SpyGlass Pharma Reports Q3 GAAP EPS of -$0.73, Missing Estimates by $0.09
SpyGlass Pharma, Inc. (SGP) reported third-quarter GAAP earnings per share of -$0.73, falling short of market expectations by $0.09. The miss highlights the ongoing financial challenges faced by the company as it continues its operational development. Despite the earnings miss, the company maintains a significant liquidity position. As of September 30, 2026, SpyGlass Pharma reported $215.8 million in cash, cash equivalents, and short-term investments. Management expects these funds to be sufficient to finance planned operations through 2028.
